Spyre Therapeutics, Inc DEFA14A, filed Apr 10, 2026
Spyre Therapeutics, Inc. (SYRE)
DEFA14A
2026-04-10
View Original
Added on
October 18, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
| Filed by the Registrant | x | |||||||||||||
| Filed by a Party other than the Registrant | ¨ | |||||||||||||
| Check the appropriate box: | ||||||||||||||
¨ | Preliminary Proxy Statement | |||||||||||||
¨ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |||||||||||||
¨ | Definitive Proxy Statement | |||||||||||||
x | Definitive Additional Materials | |||||||||||||
¨ | Soliciting Material under §240.14a-12 | |||||||||||||
Spyre Therapeutics, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
| Payment of Filing Fee (Check all boxes that apply): | ||||||||
x | No fee required. | |||||||
¨ | Fee paid previously with preliminary materials. | |||||||
¨ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. | |||||||
